Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-21-011363
Filing Date
2021-03-12
Accepted
2021-03-12 18:41:38
Documents
1
Period of Report
2020-07-01

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 5916
  Complete submission text file 0000899243-21-011363.txt   7393
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Issuer) CIK: 0000891293 (see all company filings)

EIN.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O CTI BIOPHARMA CORP. 3101 WESTERN AVE., SUITE 600 SEATTLE WA 98121
Business Address
KIRSKE DAVID (Reporting) CIK: 0001276750 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-28386 | Film No.: 21739225